Article Text

Download PDFPDF
Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer
  1. P. Sevelda*,
  2. N. Vavra*,
  3. R. Fitz*,
  4. M. Barrada*,
  5. H. Salzer*,
  6. M. Baur and
  7. C. Dittrich
  1. * Oncologic Unit of the 1st Department of Gynecology & Obstetrics, University of Vienna and
  2. Department of Chemotherapy, University of Vienna, Austria
  1. Address for correspondence: Paul Sevelda, M.D., 1st Department of Gynaecology & Obstetrics, University of Vienna, Spitalgasse 23, A-1090 Vienna, Austria.


Between October 1988 and March 1991, 23 ovarian cancer patients with progressive disease whilst receiving second- or third-line polychemotherapy received subcutaneously 3.6 mg Goserelin, a GnRH analogue, at monthly intervals until further tumor progression. Four patients (17.4%) achieved partial response, 7 patients (30.4%) had stable disease and 12 patients (52.2%) showed further tumor progression. Median time to tumor progression was 8.5, 5.3 and 2.1 months, respectively (Mantel test, P = 0.0003). Ten out of 11 patients who showed partial response or no change had grade 2 or grade 3 tumors. We conclude that Goserelin shows evidence of antitumor activity also in grade 2 and grade 3 ovarian carcinoma. It offers a therapeutic alternative to a group of patients, in whom we usually terminate cytotoxic treatment.

  • advanced disease
  • GnRH-analogue
  • Goserelin
  • ovarian carcinoma.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.